India, July 16 -- Aptorum Group Ltd. (APM), a clinical-stage biopharmaceutical company, on Wednesday announced a definitive all-stock merger agreement with DiamiR Biosciences. The deal is expected to close in the fourth quarter of 2025.
Shares of Aptorum are increasing by around 171% in the premarket trading.
Under the agreement, Aptorum Group will re-domicile to Delaware before completing the merger with DiamiR.
After the merger, DiamiR shareholders will own about 70% of the combined company, while existing Aptorum shareholders will retain 30%.
DiamiR will retain its name and become a wholly owned subsidiary of Aptorum upon completion.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The combined c...